Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1337 other investors.
On July 27, 2022, CellaVision® announces the launch of DIFF-Line ™ by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago.
DIFF-Line ™ by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox.
Redeyes view on the Q2 report. With a powerful report and above our estimates, we adjust our forecasts for the rest of the current year. We increase our Base case to SEK 370 (340) and fair value range to SEK 230 – 520 (220 – 490) per share.
April 1-June 30, 2022
CellaVision AB (publ) will publish the Interim report for the second quarter, on July 20, 2022 at 7:20 CEST. The report will be available at ir.cellavision.com
In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CEST where Simon Østergaard, President & CEO, will present and comment the report.
CellaVision invites institutional investors, financial analysts and media to join its Capital Markets Day on June 16, 2022.
During the event, CellaVision’s executive management will present the next exciting phase of our strategic vision: The Power of Focus – Enhancing the Future of Microscopy.
Join us for an update on our operational priorities and focused insights on new growth opportunities over the next five years.
The following resolutions were passed at the Annual General Meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 11 May 2022 in Lund.
Redeyes view on the Q1 report. With a report slightly above our estimates, we only make minor adjustments to our forecasts for the current year. We leave our Base case at SEK 340 unchanged.
Organic sales growth:Q1, 2022: 15% (7)
EBITDA margin:Q1, 2022: 36% (34)
1 January-31 March 2022
CellaVision AB (publ) will publish the Interim report for the first quarter, on May 10, 2022 at 7:20 CEST. The report will be available at www.cellavision.com
CellaVision will host a Capital Markets Day on June 16, 2022. During the day, executive management will present the company’s updated strategic direction, which aims to develop and broaden the company’s operations over the next five years. The event is planned to be held at CellaVision head quarter in Lund. Invitation will be sent out closer to the event.